image
Nephros, Inc. NEPH
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
Watchlist
$ 1.95
-4.41 %
$ 20.7 M
Market Cap
195.0
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one NEPH stock under the worst case scenario is HIDDEN Compared to the current market price of 1.95 USD, Nephros, Inc. is HIDDEN

NEPH Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one NEPH stock under the base case scenario is HIDDEN Compared to the current market price of 1.95 USD, Nephros, Inc. is HIDDEN

NEPH Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one NEPH stock under the best case scenario is HIDDEN Compared to the current market price of 1.95 USD, Nephros, Inc. is HIDDEN

NEPH Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart NEPH

image
1M 20%
6M 34%
1Y -3%
3Y -132%
5Y -264%
All
$2.2$2.2$2.1$2.1$2.0$2.0$1.9$1.9$1.8$1.8$1.7$1.7$1.6$1.6$1.5$1.5$1.4$1.4$1.3$1.315 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
14.2 M REVENUE
-0.53%
Growth Rates
1Year -0.53%
3Years 10.83%
5Years 6.51%
7Years 20.64%
10Years 23.27%
6 K OPERATING INCOME
100.38%
Growth Rates
1Year 100.38%
3Years 26.02%
5Years 14.89%
7Years 10.43%
10Years 7.19%
74 K NET INCOME
104.70%
Growth Rates
1Year 104.70%
3Years 26.39%
5Years 15.14%
7Years 11.12%
10Years 7.23%
-492 K OPERATING CASH FLOW
-59.49%
Growth Rates
1Year -59.49%
3Years 29.71%
5Years 26.39%
7Years -30.34%
10Years 14.99%
-50 K INVESTING CASH FLOW
33.33%
Growth Rates
1Year 33.33%
3Years 16.21%
5Years 19.83%
7Years 0.00%
10Years 0.00%
-5 K FINANCING CASH FLOW
93.67%
Growth Rates
1Year 93.67%
3Years -0.70%
5Years -0.05%
7Years -0.04%
10Years -0.02%
3.87 M REVENUE
10.01%
Growth Rates
1Year -0.53%
3Years 10.83%
5Years 6.51%
7Years 20.64%
10Years 23.27%
317 K OPERATING INCOME
53.88%
Growth Rates
1Year 100.38%
3Years 26.02%
5Years 14.89%
7Years 10.43%
10Years 7.19%
349 K NET INCOME
90.71%
Growth Rates
1Year 104.70%
3Years 26.39%
5Years 15.14%
7Years 11.12%
10Years 7.23%
1.3 M OPERATING CASH FLOW
309.31%
Growth Rates
1Year -59.49%
3Years 29.71%
5Years 26.39%
7Years -30.34%
10Years 14.99%
0 INVESTING CASH FLOW
0.00%
Growth Rates
1Year 33.33%
3Years 16.21%
5Years 19.83%
7Years 0.00%
10Years 0.00%
-1 K FINANCING CASH FLOW
0.00%
Growth Rates
1Year 93.67%
3Years -0.70%
5Years -0.05%
7Years -0.04%
10Years -0.02%
Balance Sheet Nephros, Inc.
image
Current Assets 8.3 M
Cash & Short-Term Investments 3.76 M
Receivables 1.78 M
Other Current Assets 2.76 M
Non-Current Assets 2.91 M
Long-Term Investments 0
PP&E 1.54 M
Other Non-Current Assets 1.37 M
33.54 %15.89 %24.59 %13.72 %12.26 %Total Assets$11.2m
Current Liabilities 1.56 M
Accounts Payable 649 K
Short-Term Debt 348 K
Other Current Liabilities 565 K
Non-Current Liabilities 1.06 M
Long-Term Debt 1.06 M
Other Non-Current Liabilities 0
24.72 %13.26 %21.52 %40.50 %Total Liabilities$2.6m
EFFICIENCY
Earnings Waterfall Nephros, Inc.
image
Revenue 14.2 M
Cost Of Revenue 5.44 M
Gross Profit 8.72 M
Operating Expenses 8.72 M
Operating Income 6 K
Other Expenses -68 K
Net Income 74 K
16m16m14m14m12m12m10m10m8m8m6m6m4m4m2m2m0014m(5m)9m(9m)6k68k74kRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
61.59% GROSS MARGIN
61.59%
Averages
1Year 61.59%
3Years 56.02%
5Years 56.13%
7Years 56.55%
10Years 56.63%
0.04% OPERATING MARGIN
0.04%
Averages
1Year 0.04%
3Years -18.20%
5Years -29.78%
7Years -33.42%
10Years -59.20%
0.52% NET MARGIN
0.52%
Averages
1Year 0.52%
3Years -27.99%
5Years -35.84%
7Years -38.54%
10Years -58.05%
0.86% ROE
0.86%
Averages
1Year 0.86%
3Years -49.65%
5Years -44.46%
7Years -54.27%
10Years -99.18%
0.66% ROA
0.66%
Averages
1Year 0.66%
3Years -26.40%
5Years -25.67%
7Years -26.84%
10Years -39.51%
0.05% ROIC
0.05%
Averages
1Year 0.05%
3Years -30.00%
5Years -29.20%
7Years -29.79%
10Years -51.18%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Nephros, Inc.
image
1m1m00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)(7m)(7m)(8m)(8m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 74 K
Depreciation & Amortization 137 K
Capital Expenditures -55 K
Stock-Based Compensation 153 K
Change in Working Capital -1.55 M
Others 56 K
Free Cash Flow -547 K
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Nephros, Inc.
image
NEPH has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 4
6. Ownership
Insider Ownership Nephros, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
123 K USD 2
9-12 MONTHS
7. News
Nephros to Participate in the Benchmark Company Annual Discovery One-on-One Investor Conference on December 11, 2024 in NYC SOUTH ORANGE, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will be participating in the Benchmark Company 13th Annual Discovery One-on-One Investor Conference. The event is scheduled for Wednesday, December 11, 2024, at the New York Athletic Club in New York City. globenewswire.com - 4 months ago
Nephros, Inc. (NEPH) Q3 2024 Earnings Call Transcript Nephros, Inc. (NASDAQ:NEPH ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Kirin Smith - PCG Advisory Robert Banks - President & Chief Executive Officer Judy Krandel - Chief Financial Officer Conference Call Participants Jeremy Pearlman - Maxim Group Ralph Weil - R. Weil Investment Management Operator Good day, and welcome to the Nephros Inc. Third Quarter 2024 Financial Results Conference Call. seekingalpha.com - 5 months ago
Nephros Schedules Third Quarter 2024 Financial Results Conference Call SOUTH ORANGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its third-quarter financial results on Thursday, November 7, 2024 after market close and will host a conference call that same day at 4:30pm ET. globenewswire.com - 5 months ago
Nephros Delivers Critical Disaster Response to Support Hospitals and Care Facilities Impacted by Hurricanes Helene and Milton SOUTH ORANGE, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH) Nephros, Inc., a leader in advanced filtration technology, is proud to announce its rapid response to the recent hurricanes which devastated parts of the southeastern United States. Leveraging its significant disaster and emergency response capabilities, Nephros provided crucial water filtration solutions to multiple healthcare and nursing care facilities affected by the storms, ensuring a safe supply of water to patients and staff amid recovery efforts. globenewswire.com - 5 months ago
Nephros, Inc. (NEPH) Q2 2024 Earnings Call Transcript Nephros, Inc. (NEPH) Q2 2024 Earnings Call Transcript seekingalpha.com - 8 months ago
Nephros Announces Financial Results for Quarter Ended June 30, 2024 Second-Quarter Net Revenue of $3.3 Million; New Accounts Help Drive Growth in Core Programmatic Business SOUTH ORANGE, NJ, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the second quarter ended June 30, 2024. Financial Highlights* Net revenue of $3.3 million, a decrease of 8% over Q2 prior year; programmatic revenue (excluding emergency response revenue) increased 8% over Q2 prior year Net loss of $0.3 million, compared to a net loss of $0.4 million Adjusted EBITDA of ($133,000), compared to ($183,000) *Stated performance is relative to same period in the prior year unless otherwise noted. globenewswire.com - 8 months ago
Nephros Schedules Second Quarter 2024 Financial Results Conference Call SOUTH ORANGE, NJ, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its second-quarter financial results on Thursday, August 8, 2024 after market close and will host a conference call that same day at 4:30pm ET. globenewswire.com - 8 months ago
Nephros, Inc. (NEPH) Q4 2023 Earnings Call Transcript Nephros, Inc. (NASDAQ:NEPH) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET seekingalpha.com - 1 year ago
Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Net Revenue of $3.3 Million SOUTH ORANGE, NJ, March 07, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023. Financial Highlights Fourth Quarter Ended December 31, 2023 Net revenue from continuing operations was $3.3 million, compared to $2.6 million in the fourth quarter of 2022, up 27% Net loss from continuing operations was ($0.7 million), approximately equal to the same period in 2022 Adjusted EBITDA from continuing operations was ($0.1 million), compared to ($0.5 million) in the fourth quarter of 2022, an improvement of 89% Year-End 2023 Net revenue from continuing operations was $14.2 million, compared with $10.0 million in 2022, up 43% Net loss from continuing operations was ($1.6 million), compared with ($4.3 million) in 2022 Adjusted EBITDA from continuing operations was ($0.1 million), compared with ($2.4 million) in 2022, an improvement of 97% “2023 was an exciting year for Nephros. globenewswire.com - 1 year ago
Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results SOUTH ORANGE, NJ, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its fourth quarter and fiscal year financial results on Thursday March 7, 2024 after market close and will host a conference call that same day at 4:30pm ET. globenewswire.com - 1 year ago
Nephros, Inc. (NEPH) Q3 2023 Earnings Call Transcript Nephros, Inc. (NASDAQ:NEPH ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Kirin Smith - PCG Advisory Robert Banks - CEO Judy Krandel - Chief Financial Officer Andy Astor - Advisor and Interim CFO Conference Call Participants Thomas McGovern - Maxim Group Operator Good afternoon and welcome to the Nephros Inc. Third Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode. seekingalpha.com - 1 year ago
Nephros Announces Results for Quarter Ended September 30, 2023 Third-Quarter Net Revenue of $3.7 Million, a 55% Increase Over 2022; Net Loss from Continuing Operations Narrows 85% to $0.2 Million; $1.1 Million in Positive Year-to-Date Net Cash Flows from Operating Activities globenewswire.com - 1 year ago
8. Profile Summary

Nephros, Inc. NEPH

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 20.7 M
Dividend Yield 0.00%
Description Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Contact 380 Lackawanna Place, South Orange, NJ, 07079 https://www.nephros.com
IPO Date Sept. 21, 2004
Employees 31
Officers Mr. Robert Banks President, Chief Executive Officer & Director Mr. Greg Lucas President of Aether Water Systems Brianne McGuire Director of Brand, Marketing & Business Development Ms. Judy Mazzini Controller Mr. Alfred Vargas Director of Operations Vashone R. Thomas Vice President of Quality, Regulatory, & Human Resources Ms. Judy F. Krandel C.F.A. Chief Financial Officer